| OSE IMMUNOTHERAPE.EO -,20 |
| Frankreich |
| Gesundheit |
| FR0012127173 / A14QXP |
| 6OP (Frankfurt) |
| FRA:6OP, ETR:6OP, 6OP:GR |
| - |
| https://ose-immuno.com/ |
|
OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes and Paris, France, specializing in the development of first-in-class immunotherapies for immuno-oncology and immuno-inflammation. The company focuses on innovative as..
>Volltext.. |
| 52.68 Mio. EUR |
| 65.39 Mio. EUR |
| 2.7 Mio. EUR |
| -46.18 Mio. EUR |
| -38.86 Mio. EUR |
| -1.74 EUR |
| 36.47 Mio. EUR |
| 18.1 Mio. EUR |
| -35.09 Mio. EUR |
| 0.91 |
| -96.25% |
| -200.65% |
| - |
| - |
| - |
| - |
| OSE IMMUNOTHERAPEUTICS, OSE IMMUNO |
| 28.09.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|